The 1st International Oncology Treatment Forum was held in Foshan by Fosun Health, gathering 200+ oncology experts from 15 nations. The Global Oncology Collaboration Alliance was launched to build cross‑border tele‑consultation and second‑opinion networks. Sessions covered precision radiotherapy, CyberKnife, BNCT, CAR‑T and TCM‑integrated oncology. Fosun Health also unveiled its end‑to‑end navigation model for overseas cancer patients, advancing patient‑centred global medical

“Before settling on Jiahui, I received treatment proposals from hospitals in Saudi Arabia and the United States. I chose Jiahui for their prompt replies and efficient communication. This innovative solid‑tumor CAR‑T therapy was also the most accessible option for my condition,” Josh recalled. “I had never visited China before, so I was anxious. Fortunately, I met the Jiahui team, especially Dr. Xuan, who practiced medicine in the United States for two decades.

Shanghai, July 6, 2026 — Jiahui International Cancer Center (JICC) announced that a 59-year-old male patient from New Zealand has successfully finished T-cell apheresis for Satricabtagene autoleucel (CT041). This marks the first international patient to complete T-cell collection in China for the world’s first approved solid tumor CAR-T therapy, demonstrating China’s global competitiveness in translational cell therapy and showcasing Chinese innovative treatments to global pa

The earliest pivotal CAR-T trial for R/R DLBCL, utilizing CD19-targeted CAR-T with CD28 costimulatory domain. The ZUMA series has advanced to ZUMA 9 and real-world research, enrolling over 295 patients. Key findings: CD28-based CAR-T triggers rapid, severe cytokine release syndrome (CRS); 32% of patients required ICU admission for CRS. Re-administering identical CAR-T cells to partial response (PR) patients fails to boost efficacy.

Genetic testing is indispensable for hematological disease management. For acute leukemia, it supports diagnosis, prognosis assessment and treatment guidance. However, interpreting genetic mutation reports is highly complex. Clinicians must distinguish germline (inherited) mutations from somatic tumor-derived variants, clarify whether germline variants contribute to leukemia susceptibility, analyze mutation loci, variant combinations, and their impacts on prognosis and target

Wondering why leukemia patients need genetic testing? Director Zheng Qinlong explains its vital role in precision hematology care. Genetic heterogeneity drives varied chemo responses; gene sequencing guides targeted therapy, MRD surveillance and risk stratification. Comprehensive molecular profiling avoids ineffective regimens, cuts costs and enables personalized long-term treatment plans.

Many patients wonder: How long can CAR-T therapy last? Its long-term efficacy depends not only on the initial anti-tumor effect but also on the persistence of CAR-T cells in the body. Factors like T-cell quality, production process, tumor immune escape, and standardized whole-process management all affect outcomes. To improve durability, doctors recommend early intervention, optimized cell preparation, personalized targets, and long-term monitoring.

China’s first foreign patient treated with axicabtagene ciloleucel CAR-T therapy has been discharged from Shanghai Jiahui International Hospital. A Singaporean mother with refractory lymphoma chose Jiahui for its world-class care, shorter wait and lower cost vs Western countries. Supported by a full MDT team, she recovered smoothly, marking a milestone for China’s international CAR-T treatment.

The world’s first CAR-T therapy for solid tumors, Kailimei® (CT041), has been approved in China for advanced gastric cancer. A milestone breakthrough, it marks China’s leap from follower to leader in solid tumor cell therapy. Jiahui International Cancer Center is among the first to offer this innovative treatment, bringing new hope to patients.

Unlike CAR-T therapy which is mainly concentrated in hematologic malignancies, NK cell therapy has broader application scenarios. It not only shows good prospects in the treatment of solid tumors such as lung cancer, liver cancer and colorectal cancer, but also has potential value in autoimmune diseases, neurological diseases and other fields, making up for the shortcomings of existing treatment methods.

Recently, a delegation from Bangkok Hospital visited Jiahui Health, and the two sides held exchanges focusing on oncology diagnosis, treatment and innovation. The two sides focused on cutting-edge topics in clinical oncology – ranging from surgical operations to advanced and sophisticated therapies such as CAR-T, as well as the application practice of new anti-tumor drugs in China.

The application of CAR-T cell therapy provides new treatment options for patients. Clinical evidence shows that CAR-T cell therapy has achieved remarkable efficacy in hematological malignancies, with some patients even achieving complete remission. All currently approved cellular products have reported these longterm durable responses. Studies show that 83% of lymphoma patients achieve remission after receiving CAR-T cell therapy, of whom 53% achieve complete remission [2].

Malignant tumors are one of the major diseases seriously threatening human health and life, Based on existing evidence-based medical evidence, combined with domestic and international guidelines and consensuses, the Chinese Anti-Cancer Association (CACA) has formulated these Guidelines for the Clinical Application of Malignant Tumor Immunotherapy Technologies, aiming to provide assistance to clinicians engaged in clinical immunotherapy.

At the 2025 American Society of Hematology (ASH) Annual Meeting, Senior journalist Peter Goodwin from Audio Journal of Oncology invited Professor Du Juan from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine for an on-site interview regarding her team’s research: "FasTCAR-T (GC012F/AZD0120) targeting both BCMA and CD19 as a first-line treatment for newly diagnosed multiple myeloma (NDMM)."

Novel cell therapy shows potential: As an emerging cellular immunotherapy method, CAR-NK cell therapy can still be effective in patients who have failed CAR-T treatment. With mild CRS (cytokine release syndrome) reaction and good safety, it provides a new treatment option for refractory and relapsed patients and is expected to become an important treatment direction for such patients in the future;

Multiple Myeloma (MM) is the second most common hematological malignancy worldwide and the third most common in China. It originates from plasma cells in the bone marrow, which are "immune warriors" that normally synthesize antibodies to fight infection. When these cells become malignant, they proliferate uncontrollably, crowding out healthy cells and destroying bone and kidney functions. Due to its insidious onset and diverse symptoms, the misdiagnosis rate is as high as 50%

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

Lu Daopei Hospital's dual-target CAR-T saves critically ill international DLBCL patient! A 60-year-old Egyptian with massive abdominal tumor & TP53 mutations achieved remarkable recovery after CD19/CD22 CAR-T + radiotherapy. From unable to sit to walking out smiling.